In clinical studies, Tucatinib has demonstrated significant efficacy in combination with Trastuzumab and Capecitabine for patients with advanced, HER2-positive breast cancer, particularly in those with brain metastases, where traditional treatments are less effective [24,28]. Here, ERBB2 is linked to breast carcinoma.